Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge
Executive Summary
The superiority of Novartis' Clozaril over second-generation antipsychotics in the second phase of the National Institute of Mental Health's CATIE trial suggests the need to manage the serious side effects of clozapine therapy while expanding its use, study authors argue
You may also be interested in...
Switching Antipsychotics May Not Be Best Option, New CATIE Analysis Finds
Ongoing analyses of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) continue to support a benefit for Lilly's Zyprexa over other antipsychotic medications, with the latest trial results showing that Zyprexa is the only atypical where patients did better by remaining on the drug
Switching Antipsychotics May Not Be Best Option, New CATIE Analysis Finds
Ongoing analyses of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) continue to support a benefit for Lilly's Zyprexa over other antipsychotic medications, with the latest trial results showing that Zyprexa is the only atypical where patients did better by remaining on the drug
Older Antipsychotic Tops New Branded Drugs In Consumer Reports Review
Generic perphenazine is recommended as first-line treatment for schizophrenia by Consumer Reports Best Buy Drugs based on a comparison of efficacy, adverse events and cost-effectiveness of 13 antipsychotic drugs